Guizhou Bailing Group Pharmaceutical Co.Ltd(002424) disclosed in the 2021 annual report, the company achieved an annual operating revenue of 3.112 billion yuan, a year-on-year increase of 0.77%, a net profit attributable to shareholders of listed companies of 124 million yuan, a year-on-year decrease of 18.49%, and a net profit attributable to shareholders of listed companies deducting non recurring profits and losses of 848879 million yuan, a year-on-year increase of 11.59%.
The gross profit of products increased by 113 million yuan year-on-year, and the sales of “Yindan Xinnaotong soft capsule”, an exclusive drug for cardiovascular and cerebrovascular diseases, continued to rise to 1.16 billion yuan. According to the latest statistics of Intranet, in the first half of 2021, the growth rate of Yindan Xinnaotong in the terminals of public medical institutions in China was 10.13%, and the growth rate in the terminals of physical pharmacies in China is expected to reach 14.07% in the whole year.
